The Medicare Drug Price Negotiation Program is now running three cycles at once. Negotiated prices for the first ten products ...

Three documents now define how the two largest medicines regulators think about artificial intelligence in drug development.

Swiss pharma major Novartis (NOVN: VX) is under public pressure to overhaul its board after two late-stage trial failures in ...

Adneuris Therapeutics, a wholly owned subsidiary of Tris Pharma advancing a new kind of pain medicine, has announced novel ...

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending Johnson & Johnson's ...

US clinical-stage biotech Tyra Biosciences yesterday announced initial results from SURF302, its Phase II study evaluating ...

Netherlands-based Scenic Biotech, a company developing therapies that restore lysosomal function in neurodegenerative disease ...

USA-based Solstice Oncology has launched with a $225 million Series A financing to advance porustobart, a second-generation, ...

The US Food and Drug Administration (FDA) yesterday granted accelerated approval for German pharma major Bayer’s Hyrnuo ...

For the past 20 months the European Union has been running a single, shared review of the evidence behind certain new medicines, replacing part of the work that 27 countries used to do separately. The ...

Swiss pharma giant Roche today announced that the US Food and Drug Administration (FDA) has granted Priority Review to a ...

UK clinical-stage biotech Alchemab Therapeutics has appointed experienced pharma and biotech leader Dr Ben Porter-Brown as ...